Editas Medicine, Inc. (FRA:8EM)

Germany flag Germany · Delayed Price · Currency is EUR
2.061
+0.087 (4.38%)
Last updated: Dec 5, 2025, 8:04 AM CET
-3.06%
Market Cap 203.41M
Revenue (ttm) 39.53M
Net Income (ttm) -170.32M
Shares Out n/a
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 1,110
Open 2.061
Previous Close 1.975
Day's Range 2.061 - 2.061
52-Week Range 0.827 - 3.823
Beta n/a
RSI 40.66
Earnings Date Mar 5, 2026

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporate... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 246
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 8EM
Full Company Profile

Financial Performance

In 2024, Editas Medicine's revenue was $32.31 million, a decrease of -58.64% compared to the previous year's $78.12 million. Losses were -$237.09 million, 54.7% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.